Match!
Jonathan C. Poe
Duke University
Molecular biologyImmunologyB cellSignal transductionBiology
75Publications
36H-index
5,434Citations
What is this?
Publications 71
Newest
#1William McManigle (Duke University)H-Index: 2
#2Rachel A. DiCioccio (Duke University)
Last. Stefanie Sarantopoulos (Duke University)H-Index: 22
view all 19 authors...
Source
#1Jonathan C. Poe (Duke University)H-Index: 36
Last. Frances T. Hakim (NIH: National Institutes of Health)H-Index: 32
view all 18 authors...
Source
#1Jonathan C. PoeH-Index: 36
#2Wei JiaH-Index: 13
Last. Stefanie SarantopoulosH-Index: 22
view all 14 authors...
1 CitationsSource
#1Jonathan C. Poe (Duke University)H-Index: 36
#2Wei Jia (Duke University)H-Index: 13
Last. Stefanie Sarantopoulos (Duke University)H-Index: 22
view all 22 authors...
Introduction Novex® is a biosimilar of Rituximab approved in Argentina having the same indications as the reference product (Mabthera®/Rituxan®). It is commercialized by Laboratorio Elea and since its commercial launch the first national pharmacovigilance plan for a Biosimilar mAb has been implemented. Material and Methods In order to detect deviations from expected frequencies of adverse events, a prospective treatment registry for NOVEX® was implemented since beginning of commercialization (No...
10 CitationsSource
#1Masahiro Kamata (UTokyo: University of Tokyo)H-Index: 14
#2Kathleen M. Candando (Duke University)H-Index: 4
Last. Thomas F. Tedder (Duke University)H-Index: 109
view all 9 authors...
Source
#1Ioannis Kalampokis (Duke University)H-Index: 3
#2Guglielmo M. Venturi (Duke University)H-Index: 11
Last. Thomas F. Tedder (Duke University)H-Index: 109
view all 6 authors...
Objective: Regulatory B cells that inhibit immune responses through interleukin-10 (IL-10) secretion (B10 cells) have been characterized in adults with autoimmune disease. This study examines B10 cells across the entire age range of normal human development, and their changes during pediatric autoimmunity. Methods: The phenotype and numbers of blood B10 cells were examined in healthy individuals and children with autoimmunity by flow cytometry. B10 cell function was assessed by measuring the eff...
5 CitationsSource
#1Wei Jia (Duke University)H-Index: 13
#2Jonathan C. Poe (Duke University)H-Index: 36
Last. Stefanie Sarantopoulos (Duke University)H-Index: 22
view all 15 authors...
Increased B cell-activating factor (BAFF) and aberrant B cell survival and activation are associated with chronic graft versus host disease (cGVHD) in patients. Whether excessive BAFF production has a pathologic role in the development of cGVHD after allogeneic hematopoietic stem cell transplantation (allo-HCT) remains unknown. Herein, we address this hypothesis by employing BAFF knockout (KO) and BAFF overexpressing (Tg) donor mice in the major MHC mismatched C57BL/6 (B6)-to-BALB/c cGVHD model ...
2 CitationsSource
#1Jonathan C. Poe (Duke University)H-Index: 36
#2Wei Jia (Duke University)H-Index: 13
Last. Stefanie Sarantopoulos (Duke University)H-Index: 22
view all 16 authors...
1 CitationsSource
#1Yang Yang (UNC: University of North Carolina at Chapel Hill)H-Index: 11
#2Jonathan C. Poe (Duke University)H-Index: 36
Last. Cyrus Vaziri (UNC: University of North Carolina at Chapel Hill)H-Index: 31
view all 13 authors...
In cultured cancer cells the E3 ubiquitin ligase Rad18 activates Trans-Lesion Synthesis (TLS) and the Fanconi Anemia (FA) pathway. However, physiological roles of Rad18 in DNA damage tolerance and carcinogenesis are unknown and were investigated here. Primary hematopoietic stem and progenitor cells (HSPC) co-expressed RAD18 and FANCD2 proteins, potentially consistent with a role for Rad18 in FA pathway function during hematopoiesis. However, hematopoietic defects typically associated with fanc-d...
7 CitationsSource
#1Jacquelyn M. Lykken (Duke University)H-Index: 5
#2Mayuka Horikawa (Duke University)H-Index: 20
Last. Thomas F. Tedder (Duke University)H-Index: 109
view all 7 authors...
Non-Hodgkin lymphoma (NHL) is the most commonly diagnosed hematologic cancer of adults in the United States, with the vast majority of NHLs deriving from malignant B lymphocytes that express cell surface CD20. CD20 immunotherapy (rituximab) is widely used to treat NHL, even though the initial effectiveness of rituximab varies widely among patients and typically wanes over time. The mechanisms through which lymphomas initially resist or gain resistance to immunotherapy are not well established. T...
16 CitationsSource
12345678